1 Table of Contents

2	Supplementary Table 1: Reference standard definitions	2
3	Definitions	3
4	Microbiological reference standard	3
5	Extended microbiological reference standard	3
6	Composite reference standard	3
7	Supplementary Results	5
8	Bacterial load in study Ultra and routine Xpert	
9	Drug susceptibility results of study Ultras on FNABs	
10 11 12	Supplementary Figure 1 : Spaghetti and box and whiskers plots showing FNAB Ultra internal positive control quantitative information (SPC CT). (A) Study SPC CTs vs. routine SPC CTs	6
13 14	Supplementary Figure 2 : Quantitative information of Ultra (IS6110/IS1081, rpoB) and Xpert (rpoB) compared with bacillary load (MGIT960 liquid culture TTP)	7
15 16 17 18	Supplementary Table 2 : Non-head-to-head and head-to-head diagnostic accuracy analyses of Xpert and Ultra using a microbiological reference standard (MRS), extended microbiological reference standard (eMRS) and composite reference standard (CRS) for the detection of Mycobacterium tuberculosis complex DNA	8
19 20 21	Supplementary Table 3 : Study Ultra-positive patients who were culture- and cytology- negative, with information on their Ultra semi-quantitation category, previous TB status, TB treatment initiation status and patient's status after at least 12-weeks of follow-up	9
22 23 24	Supplementary Table 4 : Diagnostic accuracy of Ultra on urine measured using the microbiological reference standard (MRS) in a head-to-head analysis stratified by HIV status	11
25 26 27	Supplementary Table 5 : Diagnostic accuracy analyses (non-head-to-head top, head-to-head bottom) of routine Xpert and study Ultra (excluding traces) on FNABs using a MRS stratified by HIV status	5
28 29 30 31 32	Supplementary Table 6: Non-head-to-head and head-to-head diagnostic accuracy analyses of Xpert and Ultra using a microbiological reference standard (MRS), extended microbiological reference standard (eMRS) and composite reference standard (CRS) for the detection of Mycobacterium tuberculosis complex DNA, excluding trace positive Ultresults	
33 34 35	Supplementary Table 7 : Diagnostic accuracy analyses (non-head-to-head top, head-to-head bottom) of routine Xpert and study Ultra (reclassifying traces as negative) on FNAE using a MRS stratified by HIV status	
36 37 38	Supplementary Table 8: Non-head-to-head and head-to-head diagnostic accuracy analyses of Xpert and Ultra using a microbiological reference standard (MRS), extended microbiological reference standard (eMRS) and composite reference standard (CRS) for	

39	the detection of Mycobacterium tuberculosis complex DNA, reclassifying trace positive
40	Ultra results as negative14

Supplementary Table 1: Reference standard definitions

	MRS^*	eMRS [†]	CRS [‡]					
		Site of disease fluid						
Xpert	×	\checkmark	\checkmark					
MGIT960 Culture	✓	✓	✓					
Cytology	✓	✓	✓					
	Non-site-of disease fluid							
Smear	×	\checkmark	\checkmark					
Xpert	×	\checkmark						
Ultra	×	\checkmark	\checkmark					
MGIT960 Culture	×	\checkmark	✓					
	r	Freatment information	n					
TB treatment initiated	×	×	\checkmark					
Response to treatment	×	×	\checkmark					
self-reported by								
patient								
		Case definitions						
Reference standard	Any MRS test	Any eMRS test	Any eMRS test					
positive (Definite TB	positive	positive	positive/or TB					
cases)			treatment was					
			initiated and					
			response to					
			treatment					
			documented					
Reference standard	No MRS test	No eMRS test	No eMRS test					
negative (Non-TB	positive	positive	positive and patient					
patients)			not initiated on					
	NT / 4	NT / 4	treatment					
Probable TB	N/A	N/A	No eMRS test					
patients			positive, but					
			treatment initiated					
Unclassifiable	No positive MRS	No positive eMRS	No positive eMRS					
	test and site-of-	test and site-of-	test and site-of-					
	disease fluid culture	disease fluid culture	disease fluid culture					
	contaminated or not	contaminated or not	contaminated or not					
	done	done	done, or treatment					
	-	-	not initiated					

44 45 Abbreviations: Composite reference standard, CRS; Extended reference standard, eMRS; MGIT960 culture, Mycobacteria Growth Indicator Tube 960; Microbiological reference standard, MRS; Smear, smear microscopy;

Ultra, Xpert MTB/RIF Ultra; Xpert, Xpert MTB/RIF.

50 **Definitions**

51 Microbiological reference standard

For the microbiological reference standard (MRS), a definite TB case was defined as a fine needle aspirate (FNAB) being culture-positive or cytology-positive and a non-TB patient was defined as being FNAB culture and cytology negative. Patients were unclassifiable if they had no positive MRS test and the site-of-disease culture was either contaminated or not done or cytology was not done.

57 Extended microbiological reference standard

For the extended microbiological reference standard (eMRS), a definite TB case was defined as a FNAB or any other body fluid being culture-, smear-, routine Xpert- or Ultra- positive and a non-TB case was defined as FNAB and other body fluids being culture-, smear-, Xpert-and Ultra- negative. Patients were considered unclassifiable if they had no positive eMRS test and the site-of-disease culture was either contaminated or not done.

63 <u>Composite reference standard</u>

64 For the composite reference standard (CRS), a definite TB case was defined as a FNAB or any 65 other body fluid being culture-, smear-, Xpert- or Ultra- positive or TB treatment was initiated and response to treatment is documented; a probable-TB case was defined as a FNAB or any 66 other body fluid being culture-, smear-, Xpert- or Ultra- positive or the patient being initiated 67 68 on TB treatment after the 12-week follow up; and a non-TB case was defined as FNAB and 69 other body fluids being culture-, smear-, Xpert-and Ultra- negative, and the patient was not 70 initiated on TB treatment, and the patient was diagnosed with an alternative disease. Patients 71 were unclassifiable if they had no positive eMRS test and the site-of-disease culture was either 72 contaminated or not done, and treatment was not initiated.

73 Supplementary Results

74 Bacterial load in study Ultra and routine Xpert


75 No correlations were observed between study Ultra quantitation (IS6110/IS1081 C_T and *rpoB*

- 76 C_{Tmin}) and culture time-to-positivity (TTP) and routine Xpert quantitation (*rpoB* C_{Tmin}) and
- 77 culture TTP (**Supplementary Figure 2**).

78 Drug susceptibility results of study Ultras on FNABs


79 Of 74 study Ultra-positive patients, 70% (52/74) were rifampicin-susceptible, 4% (3/74) 80 resistant, and 26% (19/74) indeterminate (all trace). In patients who had actionable study Ultra 81 and culture results (n=84), 20% (17/84) had MTBDRplus done. Of these, 18% (3/17) were 82 MTBDRplus rifampicin-resistant and 82% (14/17) susceptible. 33% (1/3) of these MTBDR*plus* rifampicin-resistant patients were study Ultra rifampicin-resistant (one study 83 84 Ultra trace-positive, rifampicin indeterminate and the other study Ultra negative), and 57% (8/14) of MTBDR*plus* rifampicin-susceptible patients were study Ultra rifampicin-susceptible 85 (the remaining four were study Ultra trace-positive, rifampicin indeterminate and other 86 87 remaining two were study Ultra-negative).

Supplementary Figure 1: Spaghetti and box and whiskers plots showing FNAB Ultra SPC C_T. (A) Study SPC C_T vs. routine SPC C_T. (B) SPC C_T from positive and negative study Ultras. More inhibition was observed in positives. (C) SPC C_T in true-positive vs. false-negative study Ultras, showing that greater inhibition is associated with Ultra missing TBL cases. Abbreviations: FNAB, fine needle aspirate biopsy; SPC C_T; sample processing control cycle threshold value for the Xpert MTB/RIF Ultra (Ultra) internal positive control which measures PCR inhibition; Ultra, Xpert MTB/RIF Ultra.



Supplementary Figure 2: FNAB Quantitative information of Ultra (IS6110/IS1081, rpoB) and Xpert (rpoB) compared with bacillary load
(MGIT960 liquid culture TTP). (A) Study Ultra IS6110/IS1081 C_T vs. MGIT960 liquid culture TTP. (B) Study Ultra rpoB C_{Tmin} vs. MGIT960
liquid culture TTP. (C) Routine Xpert rpoB C_Tmin vs. MGIT960 liquid culture TTP. No correlations were observed. Only two culture-positive,
routine Ultra-positive FNABs were present and routine Ultra results are hence not graphed. Abbreviations: FNAB, fine needle aspirate biopsy;
TTP, culture time-to-positivity; Ultra, Xpert MTB/RIF Ultra; Xpert, Xpert MTB/RIF.





103 Supplementary Table 2: Non-head-to-head and head-to-head diagnostic accuracy analyses of Xpert and Ultra using a MRS, eMRS and CRS for

104 the detection of Mycobacterium tuberculosis complex DNA. Conclusions were like those for the MRS (Table 2). Data are %, 95% CI, and n/N

	Non-head-to-head													
		M	RS			eMRS				CRS				
		n=	96			n=	=97			n=	97			
	Sensitivity	Specificity	PPV	NPV	Sensitivity	Specificity	PPV	NPV	Sensitivity	Specificity	PPV	NPV		
Xpert	73 (58, 85) 35/48	92 (80, 98) 44/48	90 (76, 97) 35/39	77 (64, 87) 44/57	69 (55, 81) 36/52 p=0.685*	91 (79, 98) 41/45 p=0.924*	90 (76, 97) 36/40 p=0.970*	72 (58, 83) 41/57 p=0.519*	65 (52, 77) 39/60 p=0.635 [±]	97 (86, 100) 36/37 p=0.244 [±]	98 (87, 100) 39/40 p=0.166 [±]	63 (49, 76) 36/57 p=0.317 [±]		
									p=0.379¥	p=0.274 [¥]	p=0.157 [¥]	p=0.102 [¥]		
		-	130	1			131	Ĩ		n=1		1		
Ultra	85 (73, 93) 51/60 p=0.121 [‡]	69 (56, 79) 48/70 p=0.003 [‡]	70 (58, 80) 51/73 p=0.018 [‡]	84 (76, 97) 48/57 p=0.343 [‡]	83 (71, 91) 53/64 p=0.085 [‡]	69 (56, 79) 46/67 p=0.005 ‡	72 (60, 81) 53/74 p=0.024 [‡]	81 (68, 90) 46/57 p=0.271 [‡]	76 (65, 85) 58/76 p=0.147 [‡]	71 (57, 82) 39/55 p=0.001 [‡]	78 (67, 87) 58/74 p=0.006 [‡]	68 (55, 80) 39/57 p=0.554 [‡]		
Onra	r	F	F	F out of	p=0.741*	p=0.991*	p=0.815*	p=0.622*	$p=0.345^{\pm}$	$p=0.788^{\pm}$	p=0.343 [±]	p=0.132 [±]		
									p=0.207 [¥]	$p=0.778^{\text{F}}$	$p=0.238^{\text{¥}}$	p=0.047 [¥]		
						Hea	id-to-head							
		n=	92			n=92				n=92				
Xpert	72 (57, 84) 33/46	93 (82, 99) 43/46	92 (78, 98) 33/36	77 (64, 87) 43/56	67 (52, 80) 33/49 p=0.642*	93 (81, 99) 40/43 p=0.068*	92 (78, 98) 33/36 p>0.999*	71 (58, 83) 40/56 p=0.518*	64 (50, 76) 35/55 p=0.691 [±]	97 (86, 100) 36/37 p=0.382 [±]	97 (85, 100) 35/36 p=0.304 [±]	64 (50, 77) 36/56 p=0.418 [±]		
									p=0.387 [¥]	p=0.419 [¥]	p=0.304¥	p=0.147¥		
Ultra	91 (79, 98) 42/46 p=0.016 [‡]	76 (61, 87) 35/46 p=0.020 [‡]	79 (66, 89) 42/53 p=0.114 [‡]	90 (76, 97) 35/39 p=0.105 [‡]	88 (75, 95) 43/49 p=0.016 [‡] p=0.573 [*]	77 (61, 88) 33/43 p=0.035 [‡] p=0.942 [*]	81 (68, 91) 43/53 p=0.167 [‡] p=0.808 [*]	85 (69, 94) 33/39 p=0.134 [‡] p=0.498 [*]	84 (71, 92) 46/55 p=0.017 [‡] p=0.551 [±]	81 (65, 92) 30/37 p=0.025 [‡] p=0.636 [±]	87 (75, 95) 46/53 p=0.091 [‡] p=0.427 [±]	77 (61, 89) 30/39 p=0.188 [‡] p=0.389 [±]		
					F 0.070	Р 0.912	P	P	p=0.351 $p=0.252^{\text{¥}}$	p=0.583 [¥]	p=0.427 $p=0.301^{\text{¥}}$	p=0.389 p=0.129 [¥]		

105 Within rows: *MRS vs. eMRS, eMRS vs. CRS[±], MRS vs. CRS[¥]; Within columns: Xpert vs. Ultra[‡]

106 Abbreviations: CI, confidence interval; CRS, composite reference standard; eMRS, extended microbiological reference standard; MRS, microbiological reference standard;

107 NPV, Negative predictive value; PPV, Positive predictable value; Ultra, Xpert MTB/RIF Ultra; Xpert, Xpert MTB/RIF.

Supplementary Table 3: Per patient information for study Ultra-positive patients that were MRS -negative (culture- and cytology-negative) with information on their Ultra semiquantitation category, previous TB status, TB treatment initiation status and patient's status after at least 12-weeks of follow-up. Data are n/N (%).

Patient Previous ID TB		Study Ultra semi- quantitation category	Routine PCR result	Treatment initiated after 12-week follow up	Did the patient get better? (asked telephonically if patient started treatment)
FNAB038	No	Trace	Xpert-negative	No	N/A
FNAB060	No	Very Low	Xpert-negative	Yes	Yes
FNAB072	No	Very Low	Xpert-negative	No	N/A
FNAB076	No	Medium	Xpert-positive (Low)	Yes	Yes
FNAB110	No	Trace	Xpert-negative	No	N/A
FNAB114	No	Medium	Xpert-positive (Medium)	No	N/A
FNAB128	No	Trace	Xpert-negative	No	N/A
FNAB132	No	Trace	Xpert-negative	No	N/A
FNAB172	No	Low	Xpert-negative	Yes	Yes
FNAB180	Yes	Low	Xpert-negative	No	N/A
FNAB200	No	Low	Xpert-positive (Low)	Yes	Yes
FNAB206	Yes	Trace	Not done	No	N/A
FNAB210	Yes	Trace	Ultra-negative	No	N/A
FNAB214	No	Trace	Ultra-negative	No	N/A
FNAB218	Yes	Trace	Ultra-negative	No	N/A
FNAB220	No	Trace	Ultra-positive (Very low)	Yes	Yes
FNAB230	No	Trace	Ultra-negative	No	N/A
FNAB232	Yes	Medium	Ultra-positive (Medium)	Yes	Yes
FNAB245	No	Trace	Ultra-negative	No	N/A
FNAB251	Yes	Trace	Ultra-negative	No	N/A
FNAB273	No	Trace	Ultra-negative	No	N/A
FNAB403	No	Medium	Ultra-positive (Medium)	No	N/A
Overall	6/22 (27)	Trace: 13/22 (59) Very low: 2/22 (9) Low: 3/22 (14) Medium: 4/22 (18)	Xpert: 11/21 (52) positive, 3/11 (27) negative, 8/11 (73) Ultra: 10/21 (48) positive, 3/10 (30) negative, 7/10 (70)	6/22 (27)	6/6 (100)

112 Missing data: Routine PCR not done, n=1.

- 113 Abbreviations: FNAB, fine needle aspirate biopsy; PCR, polymerase chain reaction; Ultra, Xpert MTB/RIF
- 113
 Abbre

 114
 Ultra.
- 115 If the patient was not initiated on TB treatment, N/A was recorded in the last column.

116 **Supplementary Table 4:** Diagnostic accuracy of Ultra on urine or FNABs measured using the MRS in a head-to-head analysis stratified by HIV

117 status. Urine Ultra had lower sensitivity than FNAB Ultra but increased specificity (**Table 2**). Data are %, 95% CI, and n/N

		All pa	ntients		HIV-negative				HIV-positive				
		n=	:76			n=18/7	5 (24)		n=57/75 (76)				
	Sensitivity	Specificity	PPV	NPV	Sensitivity	Specificity	PPV	NPV	Sensitivity	Specificity	PPV	NPV	
Urine- Ultra	18 (7, 35) 6/33	98 (88, 100) 42/43	86 (42, 100) 6/7	61 (48, 72) 42/69	0 (0, 52) 0/5	100 (75, 100) 13/13	0/0	72 (47, 90) 13/18	21 (8, 41) 6/28 p=0.252*	97 (82, 100) 28/29 p=498*	86 (42, 100) 6/7	56 (41, 70) 28/50 p=0.228*	
Study FNAB- Ultra	91 (76, 98) 30/33 p<0.001 [‡]	60 (44, 75) 26/43 p<0.001 [‡]	64 (49, 77) 30/47 p=0.252‡	90 (73, 98) 26/29 p=0.005 [‡]	80 (28, 99) 4/5 p=0.010 [‡]	38 (14, 68) 5/13 p=0.001 [‡]	33 (10, 65) 4/12	83 (36, 100) 5/6 p=0.586 [‡]	93 (76, 99) 26/28 p<0.001 [‡] p=0.357 [*]	69 (49, 85) 20/29 p=0.005 [‡] p=0.063 [*]	74 (57, 88) 26/35 p=0.517 [‡] p=0.011 *	91 (71, 99) 20/22 p=0.004 [‡] p=0.595 [*]	

118 Missing data: Non-actionable Ultras (n=1), no HIV (n=1) in the head-to-head table.

119 Within column p-values: [‡] Urine-Ultra vs. FNAB-Ultra

120 Within row p-values: *HIV-negative vs. HIV-positive

121 Abbreviations: CI, confidence interval; CRS, composite reference standard; eMRS, extended microbiological reference standard; MRS, microbiological reference standard;

122 NPV, negative predictive value; PPV, positive predictive value; Xpert, Xpert MTB/RIF; Ultra, Xpert MTB/RIF Ultra

123 Supplementary Table 5: Non-head-to-head and head-to-head diagnostic accuracy analyses of Xpert and Ultra using a MRS, eMRS and CRS for

124 the detection of *Mycobacterium tuberculosis complex* DNA with and without exclusion of Ultra trace results. Routine Xpert results were compared

125 to study Ultra results. Ultra has similar diagnostic accuracy compared to Xpert after trace positive exclusion. Study Ultra results with trace excluded

126 were like study Ultra results. Similar trends are seen across reference standards. Data are %, 95% CI, and n/N.

						Non-	head-to-head						
		Μ	RS			eM	IRS		CRS n=97				
		n=	=96			n=	-97						
	Sensitivity	Specificity	PPV	NPV	Sensitivity	Specificity	PPV	NPV	Sensitivity	Specificity	PPV	NPV	
Xpert [®]	73 (58, 85) 35/48	92 (80, 98) 44/48	90 (76, 97) 35/39	77 (64, 87) 44/57	69 (55, 81) 36/52 p=0.685*	91 (79, 98) 41/45 p=0.924*	90 (76, 97) 36/40 p=0.510*	72 (58, 83) 41/57 p=0.519*	$\begin{array}{c} 65 \ (52, 77) \\ 39/60 \\ p{=}0.635^{\pm} \\ p{=}0.379^{\mp} \end{array}$	$\begin{array}{c} 97 \ (86, \ 100) \\ 36/37 \\ p{=}0.244^{\pm} \\ p{=}0.274^{{\tt Y}} \end{array}$	$\begin{array}{c} 98 \ (87, \ 100) \\ 39/40 \\ p{=}0.166^{\pm} \\ p{=}0.157^{\texttt{¥}} \end{array}$	$\begin{array}{c} 63 \ (49, \ 76) \\ 36/57 \\ p{=}0.317^{\pm} \\ p{=}0.102^{\texttt{¥}} \end{array}$	
		n=	:111			n=	112			n=	112		
Ultra excluding trace	83 (71, 92) 45/54 p=0.201 [‡]	84 (72, 93) 48/57 p=0.248 [‡]	83 (71, 92) 45/54 p=0.379 [‡]	84 (72, 93) 48/57 p=0.343 [‡]	81 (69, 90) 47/58 p=0.151 [‡] p=0.751 [*]	85 (73, 93) 46/54 p=0.368 [‡] p=0.887 [*]	85 (73, 94) 47/55 p=0.510 [‡] p=0.760 [*]	81 (68, 90) 46/57 p=0.271 [‡] p=0.622 [*]	74 (62, 84) 51/69 $p=0.272^{\ddagger}$ $p=0.341^{\pm}$ $p=0.210^{¥}$	91 (78, 97) 39/43 p=0.224 [‡] p=0.413 [±] p=0.340 [¥]	$\begin{array}{c} 93 \ (82, 98) \\ 51/55 \\ p{=}0.304^{\circ} \\ p{=}0.221^{\pm} \\ p{=}0.130^{\text{¥}} \end{array}$	$\begin{array}{c} 68 \ (55, \ 80) \\ 39/57 \\ p{=}0.554^{\ddagger} \\ p{=}0.132^{\pm} \\ \textbf{p{=}0.047^{\texttt{y}}} \end{array}$	
∆ Trace excluded [∲]	-2 (-15, 12) p=0.808 [§]	+15 (1, 30) p=0.041 [§]	+13 (-1, 28) p=0.081 [§]	0 (-13, 13) p>0.999 [§]	-2 (-15, 12) p=0.799 [§]	+16 (2, 31) p=0.034 [§]	+13 (-0.03, 28) p=0.063 [§]	0 (-14, 14) p>0.999 [§]	-2 (-16, 12) p=0.738 [§]	+20 (5, 35) p=0.016 [§]	+15 (3, 26) p=0.026 [§]	0 (-17, 17) p>0.999 [§]	
						He	ad-to-head						
		n=	=82			n=	-82		n=82				
Xpert [®]	80 (64, 91) 32/40	93 (81, 99) 39/42	91 (77, 98) 32/35	83 (69,92) 39/47	74 (59, 86) 32/43 p=0.545*	92 (79, 98) 36/39 p=0.925*	91 (77, 98) 32/35 p>0.999*	77 (62, 88) 36/47 p=0.441*	$\begin{array}{c} 69 \ (55, \ 82) \\ 34/49 \\ p{=}0.593^{\pm} \\ p{=}0.255^{\mp} \end{array}$	$\begin{array}{c} 97 \ (84, \ 100) \\ 32/33 \\ p{=}0.390^{\pm} \\ p{=}0.431^{\texttt{¥}} \end{array}$	97 (85, 100) 34/35 $p=0.303^{\pm}$ $p=0.303^{\mp}$	$\begin{array}{c} 68\ (53,\ 81)\\ 32/47\\ p{=}0.356^{\pm}\\ p{=}0.093^{\mp} \end{array}$	
Ultra excluding trace	90 (76, 97) 36/40 p=0.210 [‡]	83 (69, 93) 35/42 p=0.178 [‡]	84 (69, 93) 36/43 p=0.311 [‡]	90 (76, 97) 35/39 p=0.367 [‡]	86 (72, 95) 37/43 p=0.176 [‡] p=0.580 [*]	85 (69, 94) 33/39 p=0.288 [‡] p=0.875 [*]	86 (72, 95) 37/43 p=0.459 [‡] p=0.763 [*]	85 (69, 94) 33/39 p=0.353 [‡] p=0.498 [*]	$\begin{array}{c} 82 \ (68, 91) \\ 40/49 \\ p{=}0.159^{\ddagger} \\ p{=}0.567^{\pm} \\ p{=}0.266^{\texttt{¥}} \end{array}$	91 (76, 98) 30/33 $p=0.302^{\ddagger}$ $p=0.421^{\pm}$ $p=0.338^{¥}$	$\begin{array}{c} 93\ (81,\ 99) \\ 40/43 \\ p{=}0.412^{\ddagger} \\ p{=}0.291 \\ p{=}0.178^{\texttt{¥}} \end{array}$	77 (61, 89) 30/39 $p=0.363^{\ddagger}$ $p=0.389^{\pm}$ $p=0.129^{\ddagger}$	
Δ Trace excluded ^{ϕ}	-1 (-14, 11) p=0.836 [§]	+7 (-9, 24) p=0.400 [§]	+5 (-11, 20) p=0.576 [§]	0 (-13, 13) p>0.999§	-2 (-16, 12) p=0.808 [§]	+8 (-9, 25) p=0.369 [§]	+5 (-10, 20) p=0.521 [§]	0 (-16, 16) p=0.484 [§]	-2 (-17, 13) p=0.788§	+10 (-6, 26) p=0.241 [§]	+6 (-6, 18) p=0.320 [§]	0 (-18, 18) p>0.999 [§]	

- 127 Within column p-values: [‡]Xpert vs. Ultra within an analysis (non-head-to-head or head-to-head) in patients of the same HIV status (overall, negative, or positive), [§]Study
- 128 Ultra results (Supplementary Table 2) vs. study Ultra results excluding trace results within an analysis (non-head-to-head or head-to-head) in patients using different
- 129 reference standards (MRS, eMRS, or CRS).
- 130 Within row p-values: *MRS vs. eMRS, ±eMRS vs. CRS, ¥MRS vs. CRS within an analysis (non-head-to-head or head-to-head).
- 131 •Although Xpert data are already shown in Supplementary Table 2, small differences in the number of samples included occur in the head-to-head comparison. For the non-
- 132 head-to-head comparison the Xpert data are identical to that in Supplementary Table 2 but are included here for readability.
- ⁴This comparison is Ultra with traces excluded vs. Ultra with traces included and considered positive.
- 134 Abbreviations: CRS, composite reference standard; eMRS, extended microbiological reference standard; MRS, microbiological reference standard; Ultra, Xpert MTB/RIF
- 135 Ultra; Xpert, Xpert MTB/RIF.
- 136

137 Supplementary Table 6: Non-head-to-head and head-to-head diagnostic accuracy analyses of Xpert and Ultra using a MRS, eMRS and CRS for

138 the detection of Mycobacterium tuberculosis complex DNA, reclassifying trace positive Ultra results as negative. Routine Xpert results were

139 compared to study Ultra results. Ultra has similar diagnostic accuracy compared to Xpert when trace positive results are reclassified as negative.

140 Study Ultra results with trace reclassified had increased sensitivity and decreased specificity compared to normal study Ultra results. Similar trends

141 are seen across reference standards. Data are %, 95% CI, and n/N.

	Non-head-to-head													
		Μ	RS			eMRS				CRS				
		n=	=96			n=	-97		n=97					
_	Sensitivity	Specificity	PPV	NPV	Sensitivity	Specificity	PPV	NPV	Sensitivity	Specificity	PPV	NPV		
Xpert [®]	73 (58, 85) 35/48	92 (80, 98) 44/48	90 (76, 97) 35/39	77 (64, 87) 44/57	69 (55, 81) 36/52 p=0.685*	91 (79, 98) 41/45 p=0.924*	90 (76, 97) 36/40 p=0.510*	72 (58, 83) 41/57 p=0.519*	$\begin{array}{c} 65 \ (52, \ 77) \\ 39/60 \\ p{=}0.635^{\pm} \\ p{=}0.379^{\mp} \end{array}$	97 (86, 100) 36/37 $p=0.244^{\pm}$ $p=0.274^{\mp}$	$\begin{array}{c} 98 \ (87, \ 100) \\ 39/40 \\ p{=}0.166^{\pm} \\ p{=}0.157^{\texttt{¥}} \end{array}$	$\begin{array}{c} 63 \ (49, \ 76) \\ 36/57 \\ p{=}0.317^{\pm} \\ p{=}0.102^{\mp} \end{array}$		
		n=	130			n=	131			n=13	31			
Ultra with trace reclassified	75 (62, 85) 45/60 p=0.806 [‡]	87 (77, 94) 61/70 p=0.441 [‡]	83 (71, 92) 45/54 p=0.379 [‡]	80 (70, 89) 61/76 p=0.667 [‡]	73 (61, 84) 47/64 p=0.618 [‡] p=0.843 [*]	88 (78, 95) 59/67 p=0.609 [‡] p=0.871 [*]	85 (73, 94) 47/55 p=0.510 [‡] p=0.760 [*]	78 (67, 86) 59/76 p=0.451 [‡] p=0.691 [*]	$\begin{array}{c} 67 \ (55, \ 77) \\ 51/76 \\ p{=}0.797^{\ddagger} \\ p{=}0.415^{\pm} \\ p{=}0.316^{\texttt{¥}} \end{array}$	93 (82, 98) 51/55 p=0.343 [‡] p=0.389 [±] p=0.310 [¥]	$\begin{array}{c} 93 \ (82, 98) \\ 51/55 \\ p{=}0.304^{\ddagger} \\ p{=}0.221^{\pm} \\ p{=}0.130^{\texttt{¥}} \end{array}$	$\begin{array}{c} 67 \ (55,\ 77) \\ 51/76 \\ p{=}0.636^{\ddagger} \\ p{=}0.147^{\pm} \\ p{=}0.066^{\texttt{¥}} \end{array}$		
Δ Trace reclassified ^{ϕ}	-10 (-19, -1) p=0.014 §	+18 (8, 29) p<0.001 §	+13 (-1, 28) p=0.081 [§]	-4 (-17, 9) p=0.558§	+10 (-18, 1) p=0.014 [§]	+19 (8, 30) p<0.001 [§]	+13 (-0.03, 28) p=0.063 [§]	-3 (-17, 11) p=0.667 [§]	-9 (-17, 1) p=0.008 [§]	+22 (9, 35) p=0.001 [§]	+15 (3, 26) p=0.026 [§]	+1 (-17, 14) p=0.873 [§]		
						Head	l-to-head							
-		n=	=92			n=	=92		n=92					
Xpert [®]	72 (57, 84) 33/46	93 (82, 99) 43/46	92 (78, 98) 33/36	77 (64, 87) 43/56	67 (52, 80) 33/49 p=0.642*	93 (81, 99) 40/43 p=0.932*	92 (78, 98) 33/36 p>0.999*	71 (58, 83) 40/56 p=0.518*	$\begin{array}{c} 64 \ (50, 76) \\ 35/55 \\ p{=}0.691^{\pm} \\ p{=}0.387^{\texttt{¥}} \end{array}$	$\begin{array}{c} 97 \ (86, 100) \\ 36/37 \\ p{=}0.382^{\pm} \\ p{=}0.419^{\mp} \end{array}$	97 (85, 100) 35/36 $p=0.304^{\pm}$ $p=0.303^{\mp}$	$\begin{array}{c} 64\ (50,\ 77)\\ 36/56\\ p{=}0.418^{\pm}\\ p{=}0.147^{{\tt \ \ }} \end{array}$		
Ultra with trace reclassified	78 (64, 89) 36/46 p=0.470 [‡]	85 (71, 94) 39/46 p=0.180 [‡]	84 (69, 93) 36/43 p=0.290 [‡]	80 (66, 90) 39/49 p=0.729 [‡]	76 (61, 87) 37/49 p=0.371 [‡] p=0.751 [*]	86 (72, 95) 37/43 p=0.291 [‡] p=0.763 [*]	86 (72, 95) 37/43 p=0.434 [‡] p=0.763 [*]	76 (61, 87) 37/49 p=0.637 [‡] p=0.498 [*]	$\begin{array}{c} 73 \ (59, 84) \\ 40/55 \\ p{=}0.306^{\ddagger} \\ p{=}0.747^{\pm} \\ p{=}0.521^{\texttt{¥}} \end{array}$	$\begin{array}{c} 92\ (78,98)\\ 34/37\\ p{=}0.304^{\ddagger}\\ p{=}0.409^{\pm}\\ p{=}0.323^{\texttt{¥}} \end{array}$	$\begin{array}{c} 93 \ (81, 99) \\ 40/43 \\ p{=}0.397^{\ddagger} \\ p{=}0.291^{\pm} \\ p{=}0.178^{\texttt{F}} \end{array}$	$\begin{array}{c} 69 \ (55, 82) \\ 34/49 \\ p{=}0.580^{\ddagger} \\ p{=}0.489^{\pm} \\ p{=}0.247^{\texttt{¥}} \end{array}$		
Δ Trace reclassified ^{ϕ}	-13 (-25, 1) p=0.014 [§]	+9 (-2, 19) p=0.046 [§]	+5 (-11, 20) p=0.576 [§]	-10 (-25, 5) p=0.196 [§]	-12 (-23, -1) p=0.014 [§]	+9 (-2, 20) p=0.046 [§]	+5 (-10, 20) p=0.521 [§]	-9 (-26, 7) p=0.293§	-11 (-21, -1) p=0.014 [§]	+11 (-2, 24) p=0.046 [§]	+6 (-6, 18) p=0.320 [§]	-8 (-26, 11) p=0.430 [§]		

- 142 Within column p-values: [‡]Xpert vs. Ultra within an analysis (non-head-to-head or head-to-head) in patients of the same HIV status (overall, negative, or positive), [§]Study
- 143 Ultra results (Supplementary Table 2) vs. study Ultra results excluding trace results within an analysis (non-head-to-head or head-to-head) in patients using different
- 144 reference standards (MRS, eMRS, or CRS).
- 145 Within row p-values: *MRS vs. eMRS, ±eMRS vs. CRS, ¥MRS vs. CRS within an analysis (non-head-to-head or head-to-head).
- ¹⁴⁶ ^aAlthough Xpert data are already shown in Supplementary Table 2, small differences in the number of samples included occur in the head-to-head comparison. For the non-
- 147 head-to-head comparison the Xpert data are identical to that in Supplementary Table 2 but are included here for readability.
- ⁴This comparison is Ultra with traces reclassified as negative vs. Ultra with traces considered positive.
- 149 Abbreviations: CRS, composite reference standard; eMRS, extended microbiological reference standard; MRS, microbiological reference standard; Ultra, Xpert MTB/RIF
- 150 Ultra; Xpert, Xpert MTB/RIF.